10 Best Dividend Monarchs to Invest in Now

2. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is an American multinational pharmaceutical company. Despite concerns over the loss of Humira’s patent protection, AbbVie has managed to thrive, with both its revenue and share price reaching near-record highs. The company successfully navigated the challenge by diversifying its portfolio and sustaining strong performance beyond its former top-selling drug. In addition, it focused on expanding its portfolio by creating new products and pursuing acquisitions aimed at boosting growth. Thanks to these efforts, the company now benefits from two autoimmune treatments, Rinvoq and Skyrizi, which together generate more revenue than Humira did at its highest point.

In fiscal Q4 2025, AbbVie Inc. (NYSE:ABBV) reported revenue of $15.1 billion, marking a 5.6% increase from the same period the previous year and beating analyst expectations, which were set at $14.87 billion. While the company recorded a small GAAP net loss of $0.02 per share, its adjusted diluted EPS stood at $2.16, slightly topping the anticipated $2.13. For the full year 2024, combined sales of Skyrizi and Rinvoq surged 51% to reach $1.77 billion, fueled by growing global demand and expanded market presence.

AbbVie Inc. (NYSE:ABBV), one of the best Dividend Monarchs, has been growing its dividends for the past 52 years. The company offers a quarterly dividend of $1.64 per share and has a dividend yield of 3.71%, as of April 15.